| Study Number |
Title |
| 14473B |
Phase I Safety, Pharmokinetic and Pharmacodynamic Study of PF-02341066, A C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer
|
| 16802B |
Biological Endpoints in the Annihilation of Oligometastases (BEAM ON)
|
| 10-487-A |
The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
|
| 16830A |
Communication Preferences, Expectations of Benefit, and Symptom Burdens Among Advanced Cancer Patients and Partners During Patient Participation in Phase I Trials
|
| 10-652-B |
Vorinostat and Carboplatin in Patients with Advanced Solid Tumors: A Pharmacokinetic and Pharmacodynamic Study
|
| 11-0514 |
A Phase 1 2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary AntiTumor Activity of the Oral ALK EGFR Inhibitor AP26113
|
| 11-0713 |
A Phase Ib, Open-Label Pharmacokinetics and Safety Study of Hedgehog Pathway Inhibitor Vismodegib in Patients with Advanced Solid Malignancies Including Hepatocellular Carcinoma with Varying Degrees of Renal or Hepatic Function
|
| 12-1169 |
A pharmacodynamic study of sirolimus in older children and adults with advanced solid malignancies
|
| 12-1278 |
A Phase I Open-Label Dose Escalation Study of LJM716 Administered Intravenously in Patients with Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
|
| 12-1318 |
A Drug-Drug Interaction Study of Capecitabine and Celecoxib in Patients with Advanced Solid Malignancies
|
| 12-1667 |
A Phase I Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and
Efficacy of Anti-KIR (BMS-986015) Administered in Combination with Anti-PD-1 (BMS-936558) in Advanced Refractory Solid Tumors
|
| 13-0002 |
A Registry for Serial Imaging and Plasma Assessment in Advanced Solid Tumor Patients
|
Bone